Quadramet information

Cytogen Corporation today announced that an abstract relating to its flagship product QUADRAMET(R) (samarium Sm-153 lexidronam) has been accepted for
presentation at the upcoming 47th Annual Meeting of the American Society of Hematology (ASH) and has been posted by ASH on the ASH website,
http://www.hematology.org. The abstract is scheduled for presentation at the ASH Annual Meeting, which will be held December 10-13, 2005, in Atlanta, GA.

The abstract, entitled: "Synergistic Activity of the Proteasome Inhibitor PS-341 with Non-Myeloablative 153-Sm-EDTMP in a Syngeneic, Orthotopic Model of
Multiple Myeloma" (A. Goel, A. Dispenzieri, et al.), is scheduled for presentation by clinical investigators.

The abstract can be accessed online as follows at http://www.hematology.org: click on "The 2005 ASH Annual Meeting abstracts are
now available online," register as a user, enter the search term "153-Sm-EDTMP" in the search box, and click on "go."

QUADRAMET is indicated for the relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan.
  QUADRAMET is an oncology product that pairs the targeting ability of a small molecule, bone-seeking phosphonate (EDTMP) with the therapeutic
potential of radiation (samarium Sm-153).  Skeletal invasion by prostate, breast, multiple myeloma, and other cancers often creates an imbalance between
the normal process of bone destruction and formation.  QUADRAMET selectively targets such sites of imbalance, thereby delivering radioactivity to areas of
the skeleton that have been invaded by metastatic tumor.  QUADRAMET has many characteristics that the company believes are
advantageous for the treatment of pain arising from metastatic bone disease, including early onset of pain relief (patients may experience pain relief
within the first week with maximal relief generally occurring at three to four weeks after injection), predictable and reversible bone marrow toxicity or
myelosuppression, ease of administration, and length of pain relief, lasting an average of four months in responding patients.  QUADRAMET is administered
as a single intravenous injection, usually on an outpatient basis, and exhibits selective uptake in bone with little or no detectable accumulation in
soft tissue.

QUADRAMET Safety Profile
QUADRAMET causes bone marrow suppression. In clinical trials, white blood cell counts and platelet counts decreased to a nadir of approximately 40% to
50% of baseline in 123 (95%) of patients within 3 to 5 weeks after QUADRAMET, and tended to return to pretreatment levels by 8 weeks.  Because of the
unknown potential for additive effects on bone marrow, QUADRAMET should not be given concurrently with chemotherapy or external beam radiation therapy unless
the clinical benefits outweigh the risks.  Blood counts should be monitored weekly for at least 8 weeks, or until recovery of adequate bone marrow
function.  Non-hematologic adverse events that occurred in 5% or more of patients and greater than placebo were plain flare (7%), diarrhea (6%),
infection (7%), spinal cord compression (6.5%), arrhythmias (5%), and hematuria (5%).  Patients who receive QUADRAMET should be advised that for
several hours following administration, radioactivity will be present in excreted urine.  To help protect themselves and others in their environment,
precautions need to be taken for 12 hours following administration.

A copy of the full prescribing information for QUADRAMET, including warnings, precautions, adverse events and other safety information, may be
obtained in the U.S. from Cytogen Corporation by calling toll-free 800-833-3533 or by visiting the web site at http://www.cytogen.com, which is not part
of this press release.

Source: Cytogen corporate web site http://www.cytogen.com/